Recently, BeiGene, Ltd. announced financial results for the second quarter of 2020, with revenue of $65.64 million in the second quarter ($243.35 million in the same period last year).Revenue in the first half of 2020 was $120 million, down 63 per cent from the same period last year.

(note: ABRAXANE product revenue is $240000, including accrued rebates from the end-of-sale and product recall in March 2020, compared with $34.73 million in the same period in 2019.)

Among them, BeiGene, Ltd. PD-1 monoclonal antibody tirelizumab injection (trade name: Baize'an) was put on the market in December 2019, and the approved indication was second-line relapsed or refractory classical Hodgkin's lymphoma. On April 10, 2020, the second indication of urothelial cancer (a kind of bladder cancer) was successfully approved in China. In 2020, Q1 and Q2 earned $20 million and $29 million respectively from tirelizumab. Tiraizumab is expected to earn US $100 million (about 700 million yuan) this year.

Zabutinib (Baiyueze ®), mainly used for the treatment of potent BTK inhibitors, was first approved by FDA in November 2019 and listed as a "breakthrough therapy" and approved in China in June 2020. Earlier, Baiji reported first-quarter sales of $720000 in the United States, $6.97 million in the United States and China in the second quarter, and cumulative sales of $7.69 million in the first half. Zebutini's annual income in 2020 is expected to be $15 million (about 108 million yuan).

It is worth mentioning that Baiji said that its total revenue decreased in the quarter compared with the same period last year, mainly due to the lack of cooperation revenue since the termination of the Baize an ®cooperation agreement with Xinji in June 2019, and the decline in sales since NMPA suspended ABRAXANE sales in China and product recalls in March 2020.

The R & D expenditure in the second quarter was US $280 million, plus the cumulative R & D investment in the first half of the first quarter was US $590 million. The loss on net profit this year is expected to widen further.